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Lipoprotein(a) (Lp[a]) is a complex of a low-density 
lipoprotein (LDL)-like particle and apolipoprotein-B100 
covalently bound to apolipoprotein (a) (apo[a]). Lp(a) was 
first described about 50 years ago (1963) by Kåre Berg, 
who found that high serum levels of Lp(a) are inherited 
and associated with an increased risk of premature 
cardiovascular disease (CVD)1. Apo(a) is composed of 
repeated loop-shaped units called kringles, the sequences 
of which are highly similar to a kringle shape present 
in the fibrinolytic pro-enzyme plasminogen. Variability 
in the number of repeated kringle units in the apo(a) 
molecule gives rise to differently sized Lp(a) isoforms 
in the population. Based on the similarity of Lp(a) to 
both LDL and plasminogen, it has been hypothesised 
that the function of this lipoprotein may represent a link 
between atherosclerosis and thrombosis. Lp(a) is able 
to pass through the intima of blood vessels in humans 
and animals. Accordingly, high plasma levels of Lp(a) 
may share with LDL atherogenicity, and may stimulate 
lipid peroxidation and infiltration, smooth muscle cell 
proliferation and inflammation in the arterial intima in 
humans. 
Utermann et al. highlighted an inverse relationship 
between the size of the apo(a) isoform and the Lp(a) 
concentration2-4. In 1990, Rosengren et al. examined 
the association between plasma Lp(a) concentration 
and coronary heart disease (CHD). They found that 
men with CHD had significantly higher serum Lp(a) 
levels than controls. The incidence of CHD in men with 
the highest fifth of serum Lp(a) levels (cut-off point 
365 mg/L) was double that in men with the lowest four-
fifths of concentrations. Logistic regression analysis 
showed that plasma Lp(a) levels were significantly 
associated with CHD, independently of other risk 
factors5. Similar conclusions were reported in the same 
year by Niendorf et al., in 1993 by Schreiner et al. and 
in 1994 by Valentine et al. who furtherly confirmed that 
Lp(a) had a role in the pathogenesis of atherosclerosis 
and was an independent and predictive risk factor for 
intima-media carotid thickening in individuals without 
CVD, and for premature peripheral vascular disease 
among white men6-8. In 1994, Cremer et al. suggested 
that Lp(a) and fibrinogen should be seriously considered 
as additional risk factors and should be included 
in diagnostic sets for the estimation of myocardial 
infarction (MI) risk correlates9. 
In a meta-analysis in 2007, Smolders et al. evaluated 
31 studies including 56,010 subjects with >4,609 stroke 
events. In case-control studies (23, corresponding to 
2,600 strokes) unadjusted mean Lp(a) concentration 
was more frequently elevated in stroke patients. In 
nested case-control studies (three, corresponding to 364 
strokes) Lp(a) was not a risk factor for incident stroke. 
On the other hand, in prospective cohort studies (five 
with >1,645 strokes), incident stroke was more frequent 
in patients in the highest tertile of Lp(a) distribution 
compared with those in the lowest tertile of Lp(a). The 
authors concluded that high Lp(a) levels were a risk 
factor for incident stroke10. 
In 2008, Kamstrup et al. studied 9,330 men and 
women from the general population in the Copenhagen 
City Heart Study. During 10 years of follow-up, 498 
participants developed MI. These authors observed a 
stepwise increase in risk of MI with increasing Lp(a) 
levels, with no evidence of a threshold effect. Extremely 
high Lp(a) levels predicted a 3- to 4-fold increase in 
the risk of MI in the general population and absolute 
10-year risks of 20% and 35% in high-risk women and 
men, respectively11. 
Erqou et al. reviewed long-term prospective studies 
which reported Lp(a) level and major vascular morbidity 
and/or cause-specific mortality. Lp(a) level was weakly 
correlated with several established vascular risk factors, 
and was stable within individuals over several years. 
The authors concluded that there was a continuous, 
independent, and modest association of Lp(a) level with 
risk of CHD and stroke, which appeared to be restricted 
to vascular endpoints12. Erqou et al. also studied the 
association of apo(a) isoforms with CVD risk and found 
that high Lp(a) levels and low molecular weight apo(a) 
isoforms were associated with a high risk of CVD. 
Moreover, subjects with smaller apo(a) isoforms had an 
approximately 2-fold higher risk of CHD or ischaemic 
stroke than those with larger proteins13. 
Karmstrup et al. reported a study carried out on 8,720 
Danish participants to investigate whether extremely 
high Lp(a) levels and/or corresponding Lp(a) risk 
genotypes could improve MI and CHD risk prediction, 
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beyond usual risk factors. They found that very high Lp(a) 
levels or the corresponding Lp(a) KIV-2/rs10455872 
risk genotype substantially improved MI and CHD 
risk prediction14,. The same authors published a 
further paper confirming that high Lp(a) levels and 
corresponding genotypes were associated with an 
increased risk of aortic valve stenosis in the general 
population, with levels >90 mg/dL predicting a 3-fold 
increased risk15. 
As a consequence of the above-mentioned findings, 
therapeutic approaches are being targeted at lowering 
Lp(a) levels. Novel pharmaceutical agents such as the 
apolipoprotein-B100 synthesis inhibitor, mipomersen, 
and proprotein convertase subtilisin/kexin type 
9 (PCSK9) inhibitors (alirocumab, evolocumab, 
bococizumab) have shown interesting, although not 
impressive, effectiveness at lowering Lp(a) levels16. 
Mipomersen may lower apolipoprotein-B100-
containing lipoproteins such as LDL and Lp(a) 
in patients at high risk of CVD. Indeed, studies 
investigating the effect of mipomersen on Lp(a) levels 
documented a reduction of 19.6-31.1% from baseline 
levels, depending on the study design17. Santos et al. 
found that mipomersen consistently and effectively 
reduced Lp(a) levels in patients with dyslipidaemia and 
cardiovascular risk18. 
PCSK9 is an enzyme involved in LDL-receptor 
degradation. PCSK9 inhibitors affect the levels of 
Lp(a). Koren et al. investigated the efficacy and safety 
of evolocumab, a monoclonal antibody against PCSK9, 
in a 52-week study in 1,104 randomised subjects. The 
authors found a median reduction of Lp(a) levels of 
roughly 30% (Figure 1)19.
Anacetrapib (MK-0859, Merck) is a cholesteryl 
ester transfer protein (CETP) inhibitor developed to 
treat hypercholesterolaemia and prevent CHD. In 
2013 a study of 407 Japanese subjects showed that 
anacetrapib, with or without atorvastatin, is effective 
at lowering LDL and raising high-density lipoprotein 
(HDL) concentrations20. Early results from the DEFINE 
(Determining the Efficacy and Tolerability of CETP 
Inhibition with Anacetrapib) phase III trial showed that 
at a dose of 100 mg/day, LDL decreased by 36%, Lp(a) 
decreased by 36.4%, while HDL increased by 138%. 
There was no increase in systolic blood pressure and 
no association with increased cardiovascular deaths 
Figure 1 - Percentage change from the phase 2 parent study baseline at week 52 in apolipoprotein B (ApoB), lipoprotein(a) 
(Lp[a]), triglycerides, high-density lipoprotein cholesterol (HDL-C), and apolipoprotein A1 (ApoA1). 
 The changes in lipid parameters from baseline in patients receiving evolocumab were all statistically significant (p<0.0001, 
except for the changes in triglycerides which were p<0.05). The reductions in lipid parameters were greater for patients 
receiving evolocumab+SOC vs SOC alone (p≤0.0002). Error bars represent the standard error. Data in parentheses 
represent interquartile ranges. Adapted from Koren et al.19. SOC: standard of care.
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or events21. The results were later updated to a 39.8% 
decrease of LDL22. Unfortunately, a study published in 
2014 found that HDL and anacetrapib levels remained 
elevated 2 to 4 years after discontinuation of the drug, 
raising considerable concern23. 
It is not surprising that at present the only suggested 
therapy to treat hyperLp(a)lipoproteinaemia (hyperLp[a]) 
is extracorporeal lipoprotein apheresis (LA), which 
reduces Lp(a) levels effectively. It is suggested that 
LA treatment be continuous (on a long-term basis) and 
administered weekly. Different LA methods have shown 
similar efficacy at lowering Lp(a) levels by about 60-
70% per therapeutic session. However, apart from one 
small-scale study, there are no randomised, controlled 
trials that firmly prove that lowering Lp(a) by LA 
reduces the risk of CVD16. 
In Germany, hyperLp(a) with Lp(a) levels ≥600 mg/L is 
officially recognised by the authorities as an indication 
for LA treatment24. In Italy, hyperLp(a) was recognised 
as an indication for treatment with LA when associated 
with premature CHD, in secondary prevention, by 
a consortium of scientific societies that, in 2009, 
developed the 2nd Italian Consensus Conference on
LDL-apheresis (recently renamed LA), but not 
specifically by regulatory authorities25. Also in 2009 
in Italy, a multicentre study showed that long-term 
treatment with LA (3.1±2.7 years; weekly and biweekly 
sessions) was at least able to stabilise CHD in the 
majority of individuals (19 subjects aged 53.8±9.3 years) 
with symptomatic hyperLp(a) (Figure 2)26.
In Germany, a large multicentre longitudinal cohort 
study enrolled 120 subjects with coronary artery disease 
(CAD) and elevated Lp(a) levels (≥95th percentile) on 
regular LA and maximum lipid-lowering therapy. The 
study was conducted to investigate the effect of Lp(a) 
lowering on the progression of CAD. LA reduced the 
median Lp(a) concentration by 73.3% and the annual 
major adverse coronary event rate per patient by 86.4%. 
Lowering Lp(a) levels by LA was recommended for 
patients in whom maximally tolerated doses of usual 
lipid-lowering medications fail to control CAD-related 
events27. 
In 2010, Stefanutti et al. reported the findings of a 
12-month study to assess LA efficacy at lowering Lp(a) 
and to compare the effects of LA with those of usual 
medical care, essentially statins. Twenty-one patients 
with hyperLp(a) and angiographically documented CAD 
were randomly assigned to LA every week or to usual 
medical care. The incidence of new CAD events/need 
for revascularisation was also monitored. The group 
treated with LA had a statistically significant reduction 
of Lp(a) levels of 57.8±9.5% compared to basal values, 
whereas in the group treated with usual medical care, 
Lp(a) increased in 1 year by 14.7±36.5%. Stepwise 
multivariate regression analysis for predictors of Lp(a) 
concentration, including type of treatment, smoking, 
hypertension, age, age at first cardiovascular event, 
initial Lp(a) and LDL cholesterol (LDL-C) levels, 
and body mass index values, was performed. Only the 
type of treatment was significantly correlated, with an 
Lp(a) variation (beta) of 0.863. The model had a R2 
adjusted relative risk of 0.725. New CAD events/cardiac 
interventions were not observed during a 1-year follow-
up. The authors concluded that LA could reasonably be 
the first-line treatment for isolated hyperLp(a) in patients 
with established CAD28. 
Leebmann et al. enrolled 170 patients with elevated 
Lp(a) levels and progressive CVD treated with regular 
LA in a prospective observational study. The Lp(a) 
concentration was reduced by 69.9±9.8% after each 
apheresis session and there was a 2-year reduction of 
major adverse cardiovascular events of 78.1%. The 
authors concluded that in patients with hyperLp(a), 
progressive CVD, and maximally tolerated lipid-
lowering medication, LA effectively lowered the 
incidence rate of cardiovascular events29. 
Likewise, Rosada et al. found that apheresis reduced 
the progression of atherosclerosis and cardiovascular 
events in a retrospective analysis of 37 patients with 
hyperLp(a) treated with LA on a regular basis30. The 
authors did, however, underline that as prospective and 
controlled trials are lacking, the therapeutic effectiveness 
of LA can only be supposed/estimated. 
Safarova et al. carried out a randomised, controlled, 
interventional study on the effect of Lp(a) reduction 
achieved by LA on diameter stenosis and minimal 
lumen diameter of coronary arteries. Thirty subjects 
were randomised into two groups: 15 patients were 
treated with atorvastatin and weekly LA, and 15 were 
given atorvastatin only. The authors found that in the 
group treated with weekly LA over 18 months, not only 
were Lp(a) levels reduced by 73±12%, but quantitative 
coronary angiography also showed a reduction in median 
percent diameter stenosis by 2.0 compared to that in 
Figure 2 - Mean plasma Lp(a) and LDL-C levels at baseline, 
and before/after LA. 
 Reproduced from Stefanutti et al.26
 Lp(a): lipoprotein(a); LDL-C: low-density lipoprotein 
cholesterol; LA: lipoprotein apheresis.
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the group treated with atorvastatin only. Safarova et al. 
concluded that specific Lp(a) apheresis for 18 months 
led to regression of coronary atherosclerosis in patients 
with stable CHD and high Lp(a) levels and achieved 
optimal target levels of LDL-C31. 
A further investigation conducted by von Dryander 
et al. found that the reduction of cardiovascular events 
associated with regular LA was more pronounced in 
patients with elevated Lp(a) levels than in patients with 
high LDL-C levels alone. The authors investigated 
the occurrence of cardiovascular events before and 
during apheresis in three groups defined by their lipid 
and lipoprotein patterns at the start of the apheresis 
treatment: group 1 (LDL-C ≥3.4 mmol/L and Lp(a) 
≤600 mg/L; n=35), group 2 (LDL-C ≤3.4 mmol/L and 
Lp(a) ≥600 mg/L n=37) and group 3 (LDL-C ≥3.4 
mmol/L and Lp(a) ≥600 mg/L; n=15). The time from 
first event until the start of LA treatment was about 10 
years in group 2, compared to 2-6 years in the other two 
groups. The rate of events per patient before beginning 
apheresis treatment was 2.1, 3.4 and 1.8 among patients 
in group 1, 2 and 3, respectively. Under apheresis 
treatment just 0.9 events per subject occurred in group 
1, 0.5 in group 2, and 0.5 in group 3. When comparing 
rates of cardiovascular events in the 2 years prior to 
starting apheresis with those in the first 2 years under 
LA, the authors observed the following reductions: 
group 1, −54%; group 2, −83%; and group 3, −83.5%. 
Interestingly, the authors suggested that the reduction 
of cardiovascular events, probably due to LA, was 
particularly substantial in subjects with high Lp(a) levels 
compared to that in patients with elevated LDL-C. The 
authors concluded that clinicians should be more focused 
on elevated Lp(a) levels as a cardiovascular risk factor32.
Different apheresis methods show similar lowering 
effects on Lp(a) of about 60-70% in a single session. 
Hovland et al. studied the effectiveness of different 
apheresis columns on lowering LDL-C and Lp(a) levels. 
They found that regardless of the apheresis column used, 
Lp(a) was lowered by approximately 70%. Moreover, 
three different LA columns reduced Lp(a) efficiently, 
with a preserved ratio between apo(a) isoforms33. 
In conclusion, it is reasonably well-established that 
Lp(a) is a cardiovascular risk factor, which is independent 
from total cholesterol, LDL-C, apolipoprotein B, 
hypertension, diabetes, obesity and smoking. Lp(a) level 
predicts the development of CVD and its prognostic 
weight is relevant when its levels are high. Lp(a) levels 
are not modulated by diet or exercise, since they appear 
to be largely genetically determined. Currently, plasma 
Lp(a) levels are not measured routinely in patients with 
CVD and genetic studies are not performed. However, 
monitoring and screening for this specific metabolic 
disorder could be considerably helpful in patients 
with a personal or family history of premature CAD, 
dyslipidaemia or hyperlipidaemia refractory to therapy. 
The European Atherosclerosis Society (EAS) Consensus 
Panel recommended that Lp(a) should be measured in 
patients with an intermediate or high risk of CVD or 
CHD. In particular, they suggested screening subjects 
presenting with:
- premature CVD; 
- familial hypercholesterolaemia;
- a family history of premature CVD and/or elevated 
Lp(a);
- recurrent CVD despite statin treatment;
- a ≥3% 10-year risk of fatal CVD according to the 
European guidelines, and 
- a ≥10% 10-year risk of fatal and/or non-fatal CHD 
according to the US guidelines34.
A novel approach in order to promote early diagnosis 
in immunohaematology and transfusion medicine 
centres would be desirable. Evaluation of Lp(a) should 
be recommended not only in already diagnosed CVD 
patients for better clinical management, but also in 
healthy donors. Early diagnosed patients, without 
complications, would benefit from prompt treatment 
to increase life expectancy, while improving the 
quality of the public health service, and preventing the 
development of new CVD events. 
Finally, novel therapies, which are biological drugs 
in most cases, may be used in the future treatment of 
hyperLp(a). Given the critical role of Lp(a) synthesis in 
determining Lp(a) levels, targeting either the synthesis 
of apo(a) and/or the assembly of Lp(a) would appear 
helpful35. Antisense oligonucleotides and thyroid 
hormone analogue therapies directed at apo(a) synthesis 
may be the promises for the future36,37. However, it must 
be acknowledged that, at least for now, the most effective 
and safe treatment available is LA.
The Authors declare no conflicts of interest.
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